Dr. Girgis is a passionate, patient centric, strategic drug developer with over 20 years of experience in small molecules, biologics and cell therapy, ranging from discovery to commercialization, with a particular emphasis on oncology. She joined Jazz Pharmaceuticals Inc in October 2022 as the Vice President and Head of Global Clinical Pharmacology and Pharmacometrics. She currently serves as the Industry Representative on the US FDA’s Pharmaceutical Science and Clinical Pharmacology Advisory Committee. Dr. Girgis is recognized as an expert in dose selection for First-in-Human and Proof of Concept studies. Over the years, she has made significant contributions to the development of several approved compounds [including abatacept (Orencia®), belatacept (Nulojix®), bortezomib (Velcade®), decitabine (Dacogen®), daratumumab (Darzalex®), ciltacabtagene autoleucel (Carvykti®), teclistamab (Tecvayli®), Talquetamab (Talvey®), and asparaginase Erwinia chrysanthemi (Rylaze®)]. Suzette has a strong commitment to mentoring and talent development and is a strong advocate of rotation programs.

Dr. Girgis earned her BPharm Degree from Cairo Univ (Egypt) and her MS and PhD in Pharmaceutical Sciences, specializing in PK/PD modeling, from the Univ of Rhode Island. After completing her studies, she began her career as a Postdoctoral Research Fellow in Clinical Pharmacokinetics at Johnson & Johnson. She later joined the Drug Metabolism and Pharmacokinetics Department of Schering-Plough (currently Merck), where she worked on early development compounds in neuroscience, cardiovascular and virology. Subsequently, she joined the clinical pharmacology department at Bristol Myers Squibb, where she worked on oncology and immunology compounds and later oversaw the clinical pharmacology activities for the Immunology Therapeutic Area. She has also directed many clinical pharmacology studies in oncology, immunology, neuroscience, cardiovascular and metabolic diseases. In 2008, Dr. Girgis rejoined Johnson & Johnson as a director in Global Clinical Pharmacology, where she took on increasing roles and responsibilities, including the US Head of Scientific and Technical Operations in the Clinical Pharmacology Department. Prior to joining Jazz, Dr. Girgis served as the Clinical Pharmacology Head of Hematologic Malignancies at Johnson & Johnson, where she developed multiple immuno-oncology compounds (including bispecifics, trispecifics and CAR-T), implemented model-informed drug development principles and oversaw the clinical pharmacology strategy of heme pipeline.

Dr. Girgis has published many manuscripts in prestigious journals including the New England Journal of Medicine and Lancet. She has presented at many scientific conferences such as ASH, ASCO, EHA, ESH, IMW, ACoP and AAPS. When not working, she enjoys spending time with her family, painting and hiking. She is also active in her Coptic church, where she volunteers her time to serve the local community.

Dr. Li is a Senior Director in Quantitative Clinical Pharmacology Department at Daiichi Sankyo Inc. She had worked on trastuzumab deruxtecan (T-DXd) and now is working with a team of clinical pharmacologists on patritumab deruxtecan (HER3-DXd).

Before joining DSI, Dr. Li has worked on both early phase and late phase programs in Eli Lilly and BMS. She was responsible for all PK/PD activities of neurodegeneration molecules in preclinical phases and supported progression into clinical of over 10 drug candidates and more than 5 First-in-Human studies. She has made significant contributions to more than 10 late phase clinical projects in immunology, neuroscience and oncology, including baricitinib, ixekizumab, donanemab and nivolumab. Her areas of expertise encompass both biologics and small molecule development. In addition, she led cross-functional initiatives such as establishing data/model repository, internal guidelines/practices and job aids.

Dr. Li received her BS in biology from Wuhan Univ, China; MS in Horticultural Sciences and PhD in Pharmaceutical Sciences from the Univ of Florida. She possesses a broad knowledge in biochemistry and molecule biology, and bioanalytical and mathematical mechanistic modeling.